Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 May 9:16:897930.
doi: 10.3389/fncel.2022.897930. eCollection 2022.

Commentary: Roles of the Cannabinoid System in the Basal Ganglia in Parkinson's Disease

Panteleimon Oikonomou  1 , Wolfgang H Jost  1
Affiliations
Comment

Commentary: Roles of the Cannabinoid System in the Basal Ganglia in Parkinson's Disease

Panteleimon Oikonomou et al. Front Cell Neurosci. .
No abstract available

Keywords: CB1 receptors; CB2 receptors; Parkinson's disease (PD); RCT - randomized controlled trial; basal ganglia; cannabinoids; commentary articles.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Comment on

References

    1. Carroll C. B., Bain P. G., Teare L., Liu X., Joint C., Wroath C. (2004). Cannabis for dyskinesia in Parkinson disease: a randomized double-blind crossover study. Neurology 63, 1245–1250. 10.1212/01.WNL.0000140288.48796.8E - DOI - PubMed
    1. Chagas M. H., Zuardi A. W., Tumas V., Pena-Pereira M. A., Sobreira E. T., Bergamaschi M. M. (2014). Effects of cannabidiol in the treatment of patients with Parkinson's disease: an exploratory double-blind trial. J. Psychopharmacol. 28, 1088–1098. 10.1177/0269881114550355 - DOI - PubMed
    1. Mesnage V., Houeto J. L., Bonnet A. M., Clavier I., Arnulf I., Cattelin F. (2004). Neurokinin B, neurotensin, and cannabinoid receptor antagonists and Parkinson disease. Clin. Neuropharmacol. 27, 108–110. 10.1097/00002826-200405000-00003 - DOI - PubMed
    1. Peball M., Krismer F., Knaus H. G., Djamshidian A., Werkmann M., Carbone F. (2020). Collaborators of the Parkinson's disease working group innsbruck. Non-motor symptoms in Parkinson's disease are reduced by nabilone. Ann. Neurol. 88, 712–722. 10.1002/ana.25864 - DOI - PMC - PubMed
    1. Sieradzan K. A., Fox S. H., Hill M., Dick J. P., Crossman A. R., Brotchie J. M. (2001). Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease: a pilot study. Neurology 57, 2108–2111. 10.1212/WNL.57.11.2108 - DOI - PubMed

LinkOut - more resources